Last reviewed · How we verify
Vancomycin - model-based dosing regimen
Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption.
Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption. Used for Serious infections caused by susceptible Gram-positive bacteria (including methicillin-resistant Staphylococcus aureus), Clostridium difficile-associated diarrhea, Endocarditis.
At a glance
| Generic name | Vancomycin - model-based dosing regimen |
|---|---|
| Sponsor | Murdoch Childrens Research Institute |
| Drug class | Glycopeptide antibiotic |
| Target | D-Ala-D-Ala peptidoglycan precursor |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Vancomycin is a glycopeptide antibiotic that binds to the D-alanyl-D-alanine terminus of peptidoglycan precursors in bacterial cell walls, blocking transglycosylation and transpeptidation reactions essential for cell wall integrity. This leads to cell wall weakening and bacterial cell lysis. The model-based dosing regimen optimizes pharmacokinetic/pharmacodynamic (PK/PD) parameters to achieve target drug exposures that maximize bacterial killing while minimizing toxicity.
Approved indications
- Serious infections caused by susceptible Gram-positive bacteria (including methicillin-resistant Staphylococcus aureus)
- Clostridium difficile-associated diarrhea
- Endocarditis
- Meningitis
Common side effects
- Nephrotoxicity (acute kidney injury)
- Ototoxicity (hearing loss)
- Red man syndrome (flushing, pruritus, erythema)
- Phlebitis at infusion site
- Fever
Key clinical trials
- Clinical Study of Individualized Vancomycin Dosing Based on Population PK Model (PHASE4)
- Improving Dosing of Vancomycin in Young Infants With Infections (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: